Begin typing your search above and press return to search.
EPUB Before Print

FULL TEXT

REVIEW
Torque Teno Virus Polymerase Chain Reaction Titer: A Promising Immunometry

Solid-organ transplant is the treatment of choice for all patients with end-stage diseases. Long-term graft function and survival rely on suitable immunosup­pressive treatment to prevent rejection. Besides this desired effect, a reduced immunocompetence in the transplant recipient increases the risk of developing infectious diseases and malignancies. An ideal biomarker should be sensitive, allow early visibility, be accessible in peripheral blood, and be associated with a known mechanism. Torque teno virus or transfusion transmitted virus is a virus that has gained attention as a possible marker of immune function. This virus rarely causes disease in healthy individuals, but torque teno viral load in immunosuppressed patients is shown to be higher than in healthy controls. Replication of torque teno virus is inversely correlated with number and especially functions of T lymphocytes. Torque teno virus could join the current list of predictive biomarkers in transplantation to detect whether the patient is over- or under-immunosuppressed. More studies are needed to confirm or disprove this possibility.


Key words : Biomarker, Immunosuppression, Transfusion transmitted virus

Introduction

Solid-organ transplant is the treatment of choice for all patients with end-stage diseases of heart, lung, liver, and kidney. Donors, both living and deceased, often have different human leukocyte antigens (HLA), resulting in most recipients needing immuno­sup­pressive drugs for life. Long-term graft function and survival rely on suitable immunosuppressive treatment to prevent rejection. Along with this desired effect, transplant recipients have reduced immunocompetence and thus increased risk of developing infectious diseases, which may lead to patient death.1 An ideal biomarker should be sensitive, have early visibility, be accessible in peripheral blood, and be associated with a known mechanism.2

The torque teno virus or transfusion-transmitted virus (TTV) is a virus that has gained attention as a possible marker of immune function because it is found in water, air, soil, and also in human body samples.3

In organ transplant, it has been understood that, although patients may develop infections as a result of overimmunosuppression, infections with TTV do not often occur. In the general population, this virus may be present but rarely causes disease in healthy individuals. However, in immunosuppressed patients, TTV viral load is higher than in healthy individuals. Replication of TTV is inversely correlated with number and especially functions of T lymphocytes.4

In kidney transplant recipients, it has been questioned whether the viral load of TTV over time actually relates to the risk of severe infection and rejection episodes. If the answer is yes, then does adjusting the immunosuppressive medication doses in kidney transplant patients according to TTV viral load decrease the risk of both infection and rejection episodes? In this work, we investigated the different opinions on TTV level as a biomarker to assess the immunocompetence of the host and intensity of immunosuppression in transplant recipients. If the viral load of TTV over time actually relates to the risk of severe infection and rejection episodes, we investigated the possibility of whether adjusting immunosuppressive doses in kidney transplant patients according to TTV viral load would decrease the risk of both infection and rejection episodes.

What Is Torque Teno Virus?
Torque teno virus is a nonenveloped, circular, single-strand DNA virus. It was first discovered in Japan in 1997 in 5 patients with acute posttransfusion non-A to G hepatitis.5 The name is derived from the Latin words torque, meaning “necklace,” and tenuis, meaning “thin.” It is also known as N22 and was assigned to the family of Anelloviridae.5

The virus is 30 to 50 nm in diameter, and the genome is 3.8?kb in length and contains 3739 base pairs expressing 3 messenger RNAs. It is estimated that >3.8 × 1010 copies/mL of TTV virions are generated in the healthy human body per day and that >90% of these are cleared by the immune system. Consequently, in cases with detectable viral load, TTV viral load remains about 102 to 108 copies/mL.6

Hsiao and colleagues5 found the prevalence of TTV in the general population may reach up to 95% in healthy Taiwanese individuals. In Egypt, however, prevalence was 60% in patients with thalassemia and 57% in healthy individuals.7

Detection of Torque Teno Virus
Various sets of primers were designed on distinct regions of the TTV genome to evaluate their capacity for detection of TTV DNA by polymerase chain reaction (PCR). Furthermore, the nucleotide sequences of amplification products were determined and compared among TTV isolates of different genotypes. The results obtained highlighted a deep influence of primer use for PCR for the detection of TTV DNA due to an extremely wide range of sequence divergence among TTV of distinct genotypes.8

Torque teno virus is transmitted by parenteral, transplacental, breast milk, respiratory, and fecal-oral routes.9 This virus can be found in most tissues and cells except red blood cells and platelets.10

Torque teno virus can be detected by quantitative or qualitative PCR techniques in different clinical specimens.11-13 Furthermore, immunoassays, including enzyme immunoassay and enzyme-linked immuno­sorbent assay, can be used to detect antibodies against ORF1 (anti-N22 polypeptide) or ORF2 proteins.14,15

Up to now, there are no widely standardized methods for TTV diagnosis. One method used is PCR, which is an accurate method; however, the application of different primers results in variable diagnostic sensitivity.16

The viral load of TTV increases under compro­mised immune response conditions.17 Replication of TTV is inversely correlated with number and especially function of T lymphocytes.18

Relationship Between Torque Teno Virus and BK Nephropathy
Since the early 2000s, an increase in the prevalence of nephropathy caused by human BK polyomavirus (BKPyV) in renal transplant recipients has resulted in a renewed interest in this pathogen. Infections with BKPyV may induce progressive disease, mainly during the first 3 to 6 months after transplant, over 3 successive stages: viruria, viraemia, and, if viral replication persists, nephropathy. However, it is difficult to predict patients after transplant who could replicate BKPyV.19

Until now, no data have been available to address whether there is any correlation between TTV and BKPyV viral load after solid-organ transplant. Herrmann and colleagues20 found that TTV viral load in serum correlated with BKPyV viral load in urine and observed a trend for the mean TTV viral load in serum to be weakly higher in patients without BK viruria compared with patients with BK viruria. In addition, the 2 patients with BK viremia in their study had no TTV DNA in urine, but both were positive for TTV in serum. Similar observations have been made by Beland and associates.21 It may also be possible that both BKPyV and TTV replicate in the urogenital tract in the same cells and use similar host factors or that BKPyV replication suppresses TTV replication. However, because of the lack of an in vitro cell culture system for TTV, it is difficult to follow-up on this hypothesis.20

Handala and colleagues24 retrospectively analyzed 116 recipients in which BKPyV loads were assessed monthly for the first 6 months and every 3 months thereafter. The authors found no differences in plasma TTV DNA levels throughout the first 3 months between patients with or without BKPyV replication and observed high variations in viral load levels with high variations between populations, with many factors seeming to influence the level of TTV replication, such as individual factors (for example, age and sex). However, many of these factors, factors related to the immunosuppressive regimen, and probably also factors specific to the virus remained unidentified. In addition, the authors did not demonstrate a clinically predictive TTV viral load threshold. This study found no correlation between TTV viral load and BKPyV replication after kidney transplant. However, this study had limita­tions, as it was a retrospective cohort study.22

Studies on larger multicenter cohorts with higher rates of BKPyV-associated nephropathy should be encouraged. In addition, further efforts should be directed at standardizing the reporting units for TTV DNAemia across centers.23

Torque Teno Virus Viral Load in Cases of Rejection
In kidney transplant recipients, the prevalence of those with detectable TTV DNA has been estimated to range between 10% and 100%.24 The prevalence of various TTV genotypes in kidney transplant recipients differs in different geographical areas; for example, genotypes 2 and 5 are the most prevalent genotypes in Brazilian kidney transplant recipients,25 whereas genotype 1 is the most common genotype in Hungary.26 The detectability of the virus in peripheral blood, stool, saliva, and pharyngeal mucus suggests several possible routes of transmission and a high probability of exposure.27

A correlation between increasing TTV levels in peripheral blood and plasma and the immune status of patients after transplant has been suggested, which indicates the possibility of exploiting post­transplant quantitative TTV analyses in solid-organ transplant recipients, particularly as a surrogate marker for immune reconstitution.28 The use of TTV is emerging as a promising marker to assess global functional immune competence and to predict posttransplant immune-related adverse events, which would eventually allow the customization of immunosuppression.

Several studies have evaluated TTV load as a biomarker for defining the net state of immuno­suppression in transplant recipients. A comparison of TTV levels in transplant recipients who received either tacrolimus- or cyclosporine-based therapy revealed that cyclosporine-treated patients had significantly lower TTV DNA levels in serum at 1 month compared with tacrolimus-treated patients.29 This study reported that TTV DNA load appears to reflect the function of the immune system after transplant, depending on the type of immunosup­pressive treatment. However, there was no association between either TTV load and infectious events or acute rejections, which suggests a limited clinical applicability as a biomarker to predict short-term outcomes related to the net state of immunosuppression. On the other hand, plasma TTV levels <7.0 log 10 copies/mL posttransplant were shown to be significantly associated with a high risk for the development of chronic rejection in lung transplant recipients.30 In concordance with these data, other investigators have found that anellovirus levels in heart and lung transplant recipients with acute rejection episodes were lower than levels in patients without rejection. It is tempting to speculate that a higher immunocompetence in TTV-negative patients at transplant could be responsible for the higher incidence of rejection episodes observed during the first year posttransplant.31

Antibody-mediated rejection (ABMR) represents one of the cardinal causes of late allograft loss after kidney transplant. Considerable increases in TTV DNA load have been shown, with a peak within the first 3 months, followed by a slow decrease over the following 2 years. In the BORTEJECT trial, 715 kidney allograft recipients were subjected to ABMR screening at a median of 6.3 years posttransplant. Forty-six of these patients (6%) were diagnosed with ABMR (44 patients with acute or chronic active ABMR, 2 with chronic inactive ABMR). Torque teno virus DNA was detected in 678 patients (95%) with a median of 2.3 × 105 copies/mL2.3 × 105 copies/mL.32

Torque teno viral load has been shown to be highest in patients screened 6 to 12 months after transplant, with a median of 3.5 × 106 copies/mL. Antibody induction therapy and tacrolimus-based initial immunosuppression were associated with 2-fold higher TTV levels. In contrast, TTV levels were significantly lower in patients on cyclosporine- or mammalian target of rapamycin inhibitor-based treatment. A remarkable finding was that initial treatment with belatacept was associated with a 45-fold increase in viral load. When the investigators32 analyzed immunosuppressive therapy at the time of screening, they found that patients on triple immunosuppression had 2-fold higher TTV levels than patients with dual immunosuppression or single therapy; in addition, lower levels were detected in patients who were off steroids or antimetabolites. Again, tacrolimus was associated with higher and cyclosporine with lower levels of TTV, without any relationship to trough levels. Finally, TTV load in patients on belatacept at the time of screening was 35 times higher.32

Torque teno viral load among ABMR-positive recipients was 4-fold lower than in patients who had no ABMR (6.6 ×104 vs 2.6 × 105 copies/mL; P = .003). A robust and linear inverse association between TTV load and ABMR was confirmed using score tests. Univariate logistic regression revealed a decrease in risk of ABMR of 0.91 per TTV log level (95% CI, 0.87-0.96; P = .001). Logistic regression models demonstrated that associations between TTV load and ABMR were independent of potential confounders. Similarly, a generalized linear model revealed an inverse independent association with TTV log level and ABMR risk (relative risk of 0.94 per TTV log level; 95% CI, 0.90-0.99; P = .02). Finally, TTV load was found to inversely correlate with mean fluorescence intensity of peak DSA, a marker that is shown to be associated with ABMR diagnosis.32

In another study, Strassl and associates33 investigated 1010 consecutive patients from the prospective Vienna Kidney Transplant Cohort Study for availability of allograft biopsies and adequately stored sera for TTV quantification by PCR. Results showed that patients with acute biopsy-proven alloreactivity according to the Banff classification (n = 33) showed lower levels of TTV in the peripheral blood compared with patients without rejection (n = 80) at a median of 43 days before biopsy. The risk of alloreactivity decreased by 10% per log level of TTV copies/mL (P = .005). They found that TTV levels >1 × 106 copies/mL excluded rejection with a sensitivity of 94%. Multivariable generalized linear modeling suggested an independent association between TTV level and alloreactivity.33

In light of the above-mentioned data from various studies, TTV could be able to join the current list of predictive biomarkers in transplantation to detect whether the patient is either over- or under-immunosuppressed. Several studies are needed to confirm or disprove the use of TTV as a biomarker.


References:

  1. Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21(st) century. Ann Transl Med. 2018;6(20):409. doi:10.21037/atm.2018.09.68
    CrossRef - PubMed
  2. van Belzen I, Kesmir C. Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment. Immunogenetics. 2019;71(2):71-86. doi:10.1007/s00251-018-1083-1
    CrossRef - PubMed
  3. Fernández-Ruiz M, López-Medrano F, Aguado JM. Predictive tools to determine risk of infection in kidney transplant recipients. Expert Rev Anti Infect Ther. 2020 May;18(5):423-441. doi:10.1080/14787210.2020.1733976
    CrossRef - PubMed
  4. Spandole S, Cimponeriu D, Berca LM, Mihaescu G. Human anelloviruses: an update of molecular, epidemiological and clinical aspects. Arch Virol. 2015;160(4):893-908. doi:10.1007/s00705-015-2363-9
    CrossRef - PubMed
  5. Hsiao KL, Wang LY, Lin CL, Liu HF. New phylogenetic groups of torque Teno virus identified in Eastern Taiwan indigenes. PLoS One. 2016;11(2):e0149901. doi:10.1371/journal.pone.0149901
    CrossRef - PubMed
  6. Maggi F, Bendinelli M. Immunobiology of the torque teno viruses and other anelloviruses. Curr Top Microbiol Immunol. 2009;331:65-90. doi:10.1007/978-3-540-70972-5-5
    CrossRef - PubMed
  7. Hassuna NA, Naguib E, Abdel-Fatah M, Mousa SMO. Phylogenetic analysis of torque teno virus in thalassemic children in Egypt. Intervirology. 2017;60(3):102-108. doi:10.1159/000480507
    CrossRef - PubMed
  8. Okamoto H, Takahashi M, Nishizawa T, et al. Marked genomic heterogeneity and frequent mixed infection of TT virus demonstrated by PCR with primers from coding and noncoding regions. Virology. 1999;259(2):428-436. doi:10.1006/viro.1999.9770
    CrossRef - PubMed
  9. Brassard J, Gagne MJ, Leblanc D, et al. Association of age and gender with torque teno virus detection in stools from diarrheic and non-diarrheic people. J Clin Virol. 2015;72:55-59. doi:10.1016/j.jcv.2015.08.020
    CrossRef - PubMed
  10. Focosi D, Antonelli G, Pistello M, Maggi F. Torquetenovirus: the human virome from bench to bedside. Clin Microbiol Infect. 2016;22(7):589-593. doi:10.1016/j.cmi.2016.04.007
    CrossRef - PubMed
  11. Pirouzi A, Bahmani M, Feizabadi MM, Afkari R. Molecular characterization of torque teno virus and SEN virus co-infection with HIV in patients from Southern Iran. Rev Soc Bras Med Trop. 2014;47(3):275-279. doi:10.1590/0037-8682-0073-2014
    CrossRef - PubMed
  12. Tyschik EA, Rasskazova AS, Degtyareva AV, Rebrikov DV, Sukhikh GT. Torque teno virus dynamics during the first year of life. Virol J. 2018;15(1):96. doi:10.1186/s12985-018-1007-6
    CrossRef - PubMed
  13. Wohlfarth P, Leiner M, Schoergenhofer C, et al. Torquetenovirus dynamics and immune marker properties in patients following allogeneic hematopoietic stem cell transplantation: a prospective longitudinal study. Biol Blood Marrow Transplant. 2018;24(1):194-199. doi:10.1016/j.bbmt.2017.09.020
    CrossRef - PubMed
  14. Wei Y, Chen M, Yang X, et al. Molecular characterization of human torque teno virus. Biomed Rep. 2015;3(6):821-826. doi:10.3892/br.2015.508
    CrossRef - PubMed
  15. Mankotia DS, Irshad M. Development of an immunoassay for detection of torque teno virus (TTV) antibodies using the N22 expression product from TTV genotype 2. Intervirology. 2017;60(5):207-216. doi:10.1159/000487481
    CrossRef - PubMed
  16. Rezahosseini O, Drabe CH, Sorensen SS, et al. Torque-teno virus viral load as a potential endogenous marker of immune function in solid organ transplantation. Transplant Rev (Orlando). 2019;33(3):137-144. doi:10.1016/j.trre.2019.03.004
    CrossRef - PubMed
  17. Focosi D, Macera L, Pistello M, Maggi F. Torque teno virus viremia correlates with intensity of maintenance immunosuppression in adult orthotopic liver transplant. J Infect Dis. 2014;210(4):667-668. doi:10.1093/infdis/jiu209
    CrossRef - PubMed
  18. Focosi D, Macera L, Boggi U, Nelli LC, Maggi F. Short-term kinetics of torque teno virus viraemia after induction immunosuppression confirm T lymphocytes as the main replication-competent cells. J Gen Virol. 2015;96(Pt 1):115-117. doi:10.1099/vir.0.070094-0
    CrossRef - PubMed
  19. Brochot E, Descamps V, Handala L, et al. BK polyomavirus in the urine for follow-up of kidney transplant recipients. Clin Microbiol Infect. 2019;25(1):112 e111-112 e115. doi:10.1016/j.cmi.2018.07.027
    CrossRef - PubMed
  20. Herrmann A, Sandmann L, Adams O, et al. Role of BK polyomavirus (BKV) and torque teno virus (TTV) in liver transplant recipients with renal impairment. J Med Microbiol. 2018;67(10):1496-1508. doi:10.1099/jmm.0.000823
    CrossRef - PubMed
  21. Beland K, Dore-Nguyen M, Gagne MJ, et al. Torque teno virus in children who underwent orthotopic liver transplantation: new insights about a common pathogen. J Infect Dis. 2014;209(2):247-254. doi:10.1093/infdis/jit423
    CrossRef - PubMed
  22. Handala L, Descamps V, Morel V, et al. No correlation between torque teno virus viral load and BK virus replication after kidney transplantation. J Clin Virol. 2019;116:4-6. doi:10.1016/j.jcv.2019.03.018
    CrossRef - PubMed
  23. Focosi D, Maggi F. Torque teno virus monitoring in transplantation: The quest for standardization. Am J Transplant. 2019;19(5):1599-1601. doi:10.1111/ajt.15194
    CrossRef - PubMed
  24. Akbari H, Piroozmand A, Dadgostar E, et al. Prevalence of transfusion-transmitted virus (TTV) infection and its association with renal post-transplantation complications in Iran. Int J Organ Transplant Med. 2018;9(3):126-131.
    CrossRef - PubMed
  25. Takemoto AY, Okubo P, Saito PK, et al. Torque teno virus among dialysis and renal-transplant patients. Braz J Microbiol. 2015;46(1):307-311. doi:10.1590/S1517-838246120131195
    CrossRef - PubMed
  26. Szladek G, Juhasz A, Asztalos L, et al. Persisting TT virus (TTV) genogroup 1 variants in renal transplant recipients. Arch Virol. 2003;148(5):841-851. doi:10.1007/s00705-002-0001-9
    CrossRef - PubMed
  27. Okamoto H. History of discoveries and pathogenicity of TT viruses. Curr Top Microbiol Immunol. 2009;331:1-20. doi:10.1007/978-3-540-70972-5_1
    CrossRef - PubMed
  28. Albert E, Solano C, Pascual T, et al. Dynamics of torque teno virus plasma DNAemia in allogeneic stem cell transplant recipients. J Clin Virol. 2017;94:22-28. doi:10.1016/j.jcv.2017.07.001
    CrossRef - PubMed
  29. Norden R, Magnusson J, Lundin A, et al. Quantification of torque teno virus and Epstein-Barr virus is of limited value for predicting the net state of immunosuppression after lung transplantation. Open Forum Infect Dis. 2018;5(4):ofy050. doi:10.1093/ofid/ofy050
    CrossRef - PubMed
  30. Jaksch P, Kundi M, Gorzer I, et al. Torque teno virus as a novel biomarker targeting the efficacy of immunosuppression after lung transplantation. J Infect Dis. 2018;218(12):1922-1928. doi:10.1093/infdis/jiy452
    CrossRef - PubMed
  31. Simonetta F, Pradier A, Masouridi-Levrat S, et al. Torque teno virus load and acute rejection after orthotopic liver transplantation. Transplantation. 2017;101(7):e219-e221. doi:10.1097/TP.0000000000001723
    CrossRef - PubMed
  32. Schiemann M, Puchhammer-Stockl E, Eskandary F, et al. Torque teno virus load-inverse association with antibody-mediated rejection after kidney transplantation. Transplantation. 2017;101(2):360-367. doi:10.1097/TP.0000000000001455
    CrossRef - PubMed
  33. Strassl R, Doberer K, Rasoul-Rockenschaub S, et al. Torque teno virus for risk stratification of acute biopsy-proven alloreactivity in kidney transplant recipients. J Infect Dis. 2019;219(12):1934-1939. doi:10.1093/infdis/jiz039
    CrossRef - PubMed


DOI : 10.6002/ect.2020.0303


PDF VIEW [100] KB.

From the 1Urology and Nephrology Center, Mansoura University, and 2Mansoura University Hospital, Mansoura, Egypt
Acknowledgements: The authors have not received any funding or grants in support of the presented research or for the preparation of this work and have no declarations of potential conflicts of interest.
Corresponding author: Salwa Mahmoud Elwasif, Dialysis and Renal Transplantation Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
Phone: +20502202222
E-mail: drsalwa22000@yahoo.com